Fig 6. Glibenclamide alters the subsets of T cells in both spleen and pancreatic-draining lymph nodes.
a) After 3 wks of treatment (mice 6 wk of age), FACS analysis showed that the treatment with glibenclamide dose 2 (solid symbols) increased the proportion of the effector subsets of CD44hiCD62L- T cells, and decreased that of the naïve subset of CD44loCD62L+ T cells in CD4+ (top panel) and CD8+ T cells (bottom panel), as compared to control values (open symbols). These changes took place in both spleen (S) and pancreatic-draining lymph nodes (PLN). b) Comparable observations were made after 6 wks of glibenclamide treatment (mice of 9 wks of age). Data are shown as scatters of individual values for the untreated control (open symbols, 5–10 mice) and the glibenclamide dose 2-treated group (solid symbols, 5–9 mice). Mean values are shown by the red lines. * p<0.05, ** p< 0.01, **** p<0.001 as compared to the untreated control group, using Mann-Whitney t-test.